• The SUPER study
    Share

Trial Status

Completed

Cancer Type

Colorectal Cancer

Protocol Title

A randomised phase III multicentre study evaluating the role of palliative surgical resection of the primary tumour in patients with metastatic colorectal cancer.

Purpose of the Study

The SUPER study assessed whether surgical resection of primary tumours in patients with stage IV colorectal cancer followed by chemotherapy reduces intestinal complications compared with initial systemic treatment with chemotherapy, reserving surgical resection of the primary to those patients who actually develop complications requiring surgical intervention.

The primary objective of the study determined whether intestinal complications decrease in those patients receiving initial palliative surgical resection of the primary tumour.

Principal Investigator

Prof Cameron Platell &
Prof Niall Tebbutt

DETAILED INFORMATION AVAILABLE

Available online at the Australian New Zealand Clinical Trial Registry (ANZCTR), please click here

Trial Status

Completed

Cancer Type

Colorectal Cancer

Conference Presentation Reference

Platell C, Gebski V, Solomon M, Hewett P, Price T, Quiene S, Wilson K, Tebbutt N. The SUPER study: a randomised phase III multicentre study evaluating the role of palliative surgical resection of the primary tumour in patients with metastatic colorectal cancer. Clinical Oncological Society of Australia (COSA) Annual Scientific Meeting; 9–11 Nov 2010; Melbourne.

Aim

The SUPER study will assess whether surgical resection of primary tumours in patients with stage IV colorectal cancer followed by chemotherapy reduces intestinal complications compared with initial systemic treatment with chemotherapy, reserving surgical resection of the primary to those patients who actually develop complications requiring surgical intervention.

Summary

The primary objective of the study will be to determine whether intestinal complications decrease in those patients receiving initial palliative surgical resection of the primary tumour.

Secondary objectives include determining the morbidity, mortality and quality of life associated with both treatment approaches; to determine the number, type and duration of systemic treatments (chemotherapy/chemoradiotherapy); and overall survival.

Principal Investigator

Professor Cameron Platell & Associate Professor Niall Tebbutt